Method of treating diabetes type 2 by administering ultrarapid acting insulin
AssigneeMannKind Corporation
InventorsPeter Richardson, Robert A. Baughman, Elizabeth Potocka, Anders Hasager Boss, Richard Petrucci
Life of this patent
Estimating the term…
Abstract
Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.
Claims11
A method of treating diabetes type 2 in a subject with well or moderately controlled fasting blood glucose (FBG) but poorly controlled post-prandial glucose (PPG), and in need of avoiding weight gain, comprising:
- selecting said patient with diabetes type 2 currently being treated with metformin but not a basal insulin who is in need of improved glycemic control and who would be a candidate for combination treatment with said metformin and an insulin secretagogue, said patient having an HbA1c level less than or equal to 8.4%;
- and
- instead combining treatment with said metformin with routinely administering an ultrarapid acting insulin (URAI) preparation with at least one established meal, wherein said treatment results in reduced weight gain as compared to metformin treatment alone.
A method of treating diabetes type 2 in a subject with well or moderately controlled fasting blood glucose (FBG) but poorly controlled post-prandial glucose (PPG), and in need of avoiding weight gain, comprising:
- selecting said patient with diabetes type 2 currently being treated with a suppressor of hepatic glucose output and an insulin secretagogue;
- discontinuing treatment with the insulin secretagogue;
- and routinely administering an ultrarapid acting insulin (URAI) preparation with at least one established meal, said patient having an HbA1c level less than or equal to 8.4%, wherein said treatment results in reduced weight gain as compared to treatment with said suppressor of hepatic glucose output and insulin secretagogue.
Dependencies are inferred from the claim text.